inclusion criteria: patients must satisfy all of the following criteria unless otherwise stated: willing and able to provide informed consent male or female patients > 18 years of age on the day of informed consent have received a confirmed diagnosis of covid-19 (positive for sars cov 2), as assessed by pcr or point-of-care within 72 hours of first dose on day 1 have mild to moderate signs or symptoms of covid-19 with onset within 5 days of first dose on day 1, at least two of the following symptoms: stuffy or runny nose sore throat shortness of breath cough fatigue myalgia headache chills or shivering feeling hot or feverish nausea vomiting diarrhea anosmia ageusia outpatient with covid-19 disease (not requiring oxygen therapy [who covid-19 clinical improvement ordinal scale, score of 3]) patient is aware of the investigational nature of this study and willing to comply with protocol treatments, blood tests, and other evaluations listed in the informed consent form (icf).

inclusion criteria: patients must satisfy all of the following criteria unless otherwise stated: willing and able to provide informed consent male or female patients > 18 years of age on the day of informed consent have received a confirmed diagnosis of covid-19 (positive for sars cov 2), as assessed by pcr or point-of-care within 72 hours of first dose on day 1 have mild to moderate signs or symptoms of covid-19 with onset within 5 days of first dose on day 1, at least two of the following symptoms: stuffy or runny nose sore throat shortness of breath cough fatigue myalgia headache chills or shivering feeling hot or feverish nausea vomiting diarrhea anosmia ageusia outpatient with covid-19 disease (not requiring oxygen therapy [who covid-19 clinical improvement ordinal scale, score of 3]) patient is aware of the investigational nature of this study and willing to comply with protocol treatments, blood tests, and other evaluations listed in the informed consent form (icf).

inclusion criteria: - patients must satisfy all of the following criteria unless otherwise stated: 1. willing and able to provide informed consent 2. male or female patients > 18 years of age on the day of informed consent 3. have received a confirmed diagnosis of covid-19 (positive for sars cov 2), as assessed by pcr or point-of-care within 72 hours of first dose on day 1 4. have mild to moderate signs or symptoms of covid-19 with onset within 5 days of first dose on day 1, at least two of the following symptoms: - stuffy or runny nose - sore throat - shortness of breath - cough - fatigue - myalgia - headache - chills or shivering - feeling hot or feverish - nausea - vomiting - diarrhea - anosmia - ageusia 5. outpatient with covid-19 disease (not requiring oxygen therapy [who covid-19 clinical improvement ordinal scale, score of 3]) 6. patient is aware of the investigational nature of this study and willing to comply with protocol treatments, blood tests, and other evaluations listed in the informed consent form (icf).

inclusion criteria: - patients must satisfy all of the following criteria unless otherwise stated: 1. willing and able to provide informed consent 2. male or female patients > 18 years of age on the day of informed consent 3. have received a confirmed diagnosis of covid-19 (positive for sars cov 2), as assessed by pcr or point-of-care within 72 hours of first dose on day 1 4. have mild to moderate signs or symptoms of covid-19 with onset within 5 days of first dose on day 1, at least two of the following symptoms: - stuffy or runny nose - sore throat - shortness of breath - cough - fatigue - myalgia - headache - chills or shivering - feeling hot or feverish - nausea - vomiting - diarrhea - anosmia - ageusia 5. outpatient with covid-19 disease (not requiring oxygen therapy [who covid-19 clinical improvement ordinal scale, score of 3]) 6. patient is aware of the investigational nature of this study and willing to comply with protocol treatments, blood tests, and other evaluations listed in the informed consent form (icf).

inclusion criteria: - patients must satisfy all of the following criteria unless otherwise stated: 1. willing and able to provide informed consent 2. male or female patients > 18 years of age on the day of informed consent 3. have received a confirmed diagnosis of covid-19 (positive for sars cov 2), as assessed by pcr or point-of-care within 72 hours of first dose on day 1 4. have mild to moderate signs or symptoms of covid-19 with onset within 5 days of first dose on day 1, at least two of the following symptoms: - stuffy or runny nose - sore throat - shortness of breath - cough - fatigue - myalgia - headache - chills or shivering - feeling hot or feverish - nausea - vomiting - diarrhea - anosmia - ageusia 5. outpatient with covid-19 disease (not requiring oxygen therapy [who covid-19 clinical improvement ordinal scale, score of 3]) 6. patient is aware of the investigational nature of this study and willing to comply with protocol treatments, blood tests, and other evaluations listed in the icf.

inclusion criteria: - patients must satisfy all of the following criteria unless otherwise stated: 1. willing and able to provide informed consent 2. male or female patients > 18 years of age on the day of informed consent 3. have received a confirmed diagnosis of covid-19 (positive for sars cov 2), as assessed by pcr or point-of-care within 72 hours of first dose on day 1 4. have mild to moderate signs or symptoms of covid-19 with onset within 5 days of first dose on day 1, at least two of the following symptoms: - stuffy or runny nose - sore throat - shortness of breath - cough - fatigue - myalgia - headache - chills or shivering - feeling hot or feverish - nausea - vomiting - diarrhea - anosmia - ageusia 5. outpatient with covid-19 disease (not requiring oxygen therapy [who covid-19 clinical improvement ordinal scale, score of 3]) 6. patient is aware of the investigational nature of this study and willing to comply with protocol treatments, blood tests, and other evaluations listed in the icf.